Sancak, Y. et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915

Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge, MA 02142, USA.
Molecular Cell (Impact Factor: 14.02). 04/2007; 25(6):903-15. DOI: 10.1016/j.molcel.2007.03.003
Source: PubMed


The heterotrimeric mTORC1 protein kinase nucleates a signaling network that promotes cell growth in response to insulin and becomes constitutively active in cells missing the TSC1 or TSC2 tumor suppressors. Insulin stimulates the phosphorylation of S6K1, an mTORC1 substrate, but it is not known how mTORC1 kinase activity is regulated. We identify PRAS40 as a raptor-interacting protein that binds to mTORC1 in insulin-deprived cells and whose in vitro interaction with mTORC1 is disrupted by high salt concentrations. PRAS40 inhibits cell growth, S6K1 phosphorylation, and rheb-induced activation of the mTORC1 pathway, and in vitro it prevents the great increase in mTORC1 kinase activity induced by rheb1-GTP. Insulin stimulates Akt/PKB-mediated phosphorylation of PRAS40, which prevents its inhibition of mTORC1 in cells and in vitro. We propose that the relative strengths of the rheb- and PRAS40-mediated inputs to mTORC1 set overall pathway activity and that insulin activates mTORC1 through the coordinated regulation of both.

Download full-text


Available from: Seong A Kang, Oct 07, 2015
1 Follower
25 Reads
    • "Indeed, the removal of all Akt phosphorylation sites from TSC-1 and TSC-2 does not lead to an increase in TORC1 activity, as judged by an absence of a growth increase in vivo (Dong and Pan 2004; Schleich and Teleman 2009); this result indicates that, under physiological conditions, Akt function does not contribute to TORC1 activation. More recently, the protein PRAS40 ( proline-rich Akt substrate 40) was proposed to link IIS to TORC1 in cultured cells (Sancak et al. 2007; Vander Haar et al. 2007). PRAS40 binds to TORC1 and prevents it from interacting with its substrates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Growth is a complex process that is intimately linked to the developmental program to form adults with proper size and proportions. Genetics is an important determinant of growth, as exemplified by the role of local diffusible molecules setting up organ proportions. In addition, organisms use adaptive responses allowing modulating the size of individuals according to environmental cues, for example, nutrition. Here, we describe some of the physiological principles participating in the determination of final individual size. Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
    Cold Spring Harbor perspectives in biology 08/2015; DOI:10.1101/cshperspect.a019117 · 8.68 Impact Factor
  • Source
    • "At the same time, Akt phosphorylates also Pras40. Pras40 is a direct TORC1 inhibitor, which functions through scaffolding of the essential TORC1 component Raptor (Sancak et al., 2007; Vander Haar et al., 2007). On the other hand, if a cell is in a low energy state TSC-mediated inhibition of TORC1 prevails. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The internal left-right (LR) asymmetry is a characteristic that exists throughout the animal kingdom from roundworms over flies and fish to mammals. Cilia, which are antenna-like structures protruding into the extracellular space, are involved in establishing LR asymmetry during early development. Humans who suffer from dysfunctional cilia often develop conditions such as heterotaxy, where internal organs appear to be placed randomly. As a consequence to this failure in asymmetry development serious complications such as congenital heart defects (CHD) occur. The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has recently emerged as an important regulator regarding symmetry breaking. The mTOR pathway governs fundamental processes such as protein translation or metabolism. Its activity can be transduced by two complexes, which are called TORC1 and TORC2, respectively. So far, only TORC1 has been implicated with asymmetry development and appears to require very precise regulation. A number of recent papers provided evidence that dysregulated TORC1 results in alterations of motile cilia and asymmetry defects. In here we give an update on what we know so far of mTORC1 in LR asymmetry development. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Biology of the Cell 05/2015; 107(9). DOI:10.1111/boc.201400094 · 3.51 Impact Factor
  • Source
    • "In Vitro mTOR Kinase Assay The mTOR kinase activity was assessed by in vitro kinase assay as described (Sancak et al., 2007). Briefly, pCDNA3-Flag-mTOR variants were transfected into HEK293T cells by calcium phosphate transfection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein kinases are therapeutic targets for human cancer. However, "gatekeeper" mutations in tyrosine kinases cause acquired clinical resistance, limiting long-term treatment benefits. mTOR is a key cancer driver and drug target. Numerous small-molecule mTOR kinase inhibitors have been developed, with some already in human clinical trials. Given our clinical experience with targeted therapeutics, acquired drug resistance in mTOR is thought likely, but not yet documented. Herein, we describe identification of a hot spot (L2185) for drug-resistant mutations, which is distinct from the gatekeeper site, and a chemical scaffold refractory to drug-resistant mutations. We also provide new insights into mTOR kinase structure and function. The hot spot mutations are potentially useful as surrogate biomarkers for acquired drug resistance in ongoing clinical trials and future treatments and for the design of the next generation of mTOR-targeted drugs. Our study provides a foundation for further research into mTOR kinase function and targeting. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Cell Reports 04/2015; 11(3). DOI:10.1016/j.celrep.2015.03.040 · 8.36 Impact Factor
Show more